Akoya BioSciencesAKYA
AKYA
About: Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
Employees: 205
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2,380% more call options, than puts
Call options by funds: $124K | Put options by funds: $5K
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
2% more funds holding
Funds holding: 59 [Q3] → 60 (+1) [Q4]
0.06% more ownership
Funds ownership: 24.43% [Q3] → 24.49% (+0.06%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
16% less capital invested
Capital invested by funds: $32.9M [Q3] → $27.8M (-$5.1M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.65
37%
upside
Avg. target
$1.75
46%
upside
High target
$1.80
50%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Canaccord Genuity Kyle Mikson 33% 1-year accuracy 9 / 27 met price target | 50%upside $1.80 | Hold Maintained | 29 Apr 2025 |
Piper Sandler David Westenberg 45% 1-year accuracy 19 / 42 met price target | 38%upside $1.65 | Neutral Maintained | 14 Apr 2025 |
Stephens & Co. Mason Carrico 15% 1-year accuracy 4 / 26 met price target | 50%upside $1.80 | Equal-Weight Downgraded | 25 Mar 2025 |
Financial journalist opinion
Based on 8 articles about AKYA published over the past 30 days
Neutral
Business Wire
8 hours ago
Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the “Amended Merger Agreement”) related to its proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA): “Quanterix's decision to press on with the Merger in the face.
Neutral
Business Wire
1 day ago
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya s.
Neutral
GlobeNewsWire
6 days ago
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer.
Neutral
GlobeNewsWire
6 days ago
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a groundbreaking collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the research and clinical community.
Neutral
GlobeNewsWire
1 week ago
Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore
The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world setting, bringing together Singapore's public healthcare and research institutions in the translational cancer research ecosystem, comprising the National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapore (NCIS), National University Hospital (NUH), National University of Singapore (NUS), Singapore General Hospital (SGH) and the Agency for Science, Technology and Research (A*STAR). The partnership between Akoya Biosciences and STCC will leverage Akoya Biosciences' PhenoCode™ Discovery IO60 Panel in the SUPER study to immunophenotype matched pairs of immuno-oncology exceptional responders and hyper-progressors through advanced spatial multiplexed analyses.
Neutral
Business Wire
2 weeks ago
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (“Quanterix” or the “Company”) (Nasdaq: QTRX), today issued a statement calling on the Company to explain its most recent purchase agreement for up to $30 million in convertible notes from Akoya Biosciences, Inc. (“Akoya”) (Nasdaq: AKYA). Tikvah's statement follows: “This announcement concerns us for several r.
Neutral
Business Wire
3 weeks ago
Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Today, Kent Lake issued a statement related to recent disclosures indicating that Quanterix has officially entered into a Securities Purchase Agreement under which Akoya Biosciences (“Akoya”) (NASDAQ: AKYA) has the ability to sell the Company up to $30 million in convertible notes. Kent Lake.
Neutral
GlobeNewsWire
4 weeks ago
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
Akoya's technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya's PhenoCycler-Fusion platform to process thousands of patients' samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and SAMBAI, a team funded through the Cancer Grand Challenges initiative, today announced that Akoya's PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research.
Neutral
Business Wire
1 month ago
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (Nasdaq: QTRX) (“Quanterix” or the “Company”), today announced that it intends to vote AGAINST the Company's proposed merger with Akoya Biosciences, Inc. (“Akoya”) (Nasdaq: AKYA) at the upcoming Quanterix Special Meeting of shareholders. As a significant investor in the Company since 2018, Tikvah believes the.
Negative
Zacks Investment Research
1 month ago
Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago.
Charts implemented using Lightweight Charts™